Proximal tubular epithelia-specific transcriptomics of diabetic mice treated with dapagliflozin

Proximal tubular epithelia-specific transcriptomics of diabetic mice treated with dapagliflozin

Based on recent clinical trials using sodium-glucose co-transporter 2 inhibitor (SGLT2i) demonstrating the significant improvement of outcomes of diabetic kidney disease (DKD), the paradigm shift from “glomerulocentric” to “tubule centric” pathophysiology in DKD progression has been highlighted. Sev...

Full description

Bibliographic Details
Main Authors:	Noriko Uehara-Watanabe, Natsuko Okuno-Ozeki, Itaru Nakamura, Tomohiro Nakata, Kunihiro Nakai, Aya Yagi-Tomita, Tomoharu Ida, Noriyuki Yamashita, Michitsugu Kamezaki, Yuhei Kirita, Satoaki Matoba, Keiichi Tamagaki, Tetsuro Kusaba
Format:	Article
Language:	English
Published:	Elsevier 2022-09-01
Series:	Heliyon
Subjects:	Diabetic nephropathy Proximal tubular epithelial cell Dapagliflozin Hypoxia
Online Access:	http://www.sciencedirect.com/science/article/pii/S240584402201903X

Similar Items

The importance of proinflammatory failed-repair tubular epithelia as a predictor of diabetic kidney disease progression
by: Aya Tomita-Yagi, et al.
Published: (2024-02-01)

Direct evidence of proximal tubular proliferation in early diabetic nephropathy
by: Noriko Uehara-Watanabe, et al.
Published: (2022-01-01)

Streptozotocin induces renal proximal tubular injury through p53 signaling activation
by: Kunihiro Nakai, et al.
Published: (2023-05-01)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
by: Kim HC, et al.
Published: (2023-04-01)

Chitosan Versus Dapagliflozin in a Diabetic Cardiomyopathy Mouse Model
by: Georgică Târtea, et al.
Published: (2024-02-01)

Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension
by: Yi Tang, et al.
Published: (2022-04-01)

Comparison of Cardioprotective Effects of Dapagliflozin and Trimetazidine in the Model of Doxorubicin-Cyclophosphamide Cardiotoxicity
by: A. A. Avagimyan, et al.
Published: (2023-11-01)

Exercise Augments the Effect of SGLT2 Inhibitor Dapagliflozin on Experimentally Induced Diabetic Cardiomyopathy, Possible Underlying Mechanisms
by: Mamdouh Eldesoqui, et al.
Published: (2022-07-01)

Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation
by: Pei-Ling Hsieh, et al.
Published: (2022-09-01)

Dapagliflozin Ameliorates Neural Damage in the Heart and Kidney of Diabetic Mice
by: Ionuț Donoiu, et al.
Published: (2023-12-01)

Practice of Dapagliflozin Application in Patients with Type 2 Diabetes Mellitus
by: L.V. Shkala, et al.
Published: (2015-08-01)

Effect of Dapagliflozin and Magnesium Supplementation on Renal Magnesium Handling and Magnesium Homeostasis in Metabolic Syndrome
by: Hwee-Yeong Ng, et al.
Published: (2021-11-01)

Dapagliflozin's effect on serum homocysteine in patients with hypertension complicated with insulin resistance
by: Xiaoqian Yu, et al.
Published: (2023-05-01)

Use of dapagliflozin in patients with advanced diabetic kidney disease
by: Hyun Sun Park, et al.
Published: (2018-09-01)

Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin
by: Carlos Escobar, et al.
Published: (2023-10-01)

Dapagliflozin attenuates hypoxia/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK
by: Kun-Ling Tsai, et al.
Published: (2021-02-01)

Early initiation of Dapagliflozin and its effect on health related quality of life in acute heart failure: a randomised controlled trial
by: Syedah Fauzia Fatima Gilani, et al.
Published: (2024-03-01)

Clinical Evaluation of Dapagliflozin in the Management of CKD: Focus on Patient Selection and Clinical Perspectives
by: Nashar K, et al.
Published: (2022-11-01)

Comparison of Extraglycemic effects of Dapagliflozin and Empagliflozin
by: Haroon Aziz, et al.
Published: (2023-06-01)

Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway
by: Liuran Li, et al.
Published: (2021-05-01)

Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring
by: Wilfried Mullens, et al.
Published: (2020-10-01)

Dapagliflozin Protects Methamphetamine-Induced Cardiomyopathy by Alleviating Mitochondrial Damage and Reducing Cardiac Function Decline in a Mouse Model
by: Shanqing He, et al.
Published: (2022-07-01)

Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin
by: Schwartz SS, et al.
Published: (2016-03-01)

SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin
by: Stephan Dobner, et al.
Published: (2023-02-01)

Investigating the Cardiovascular Benefits of Dapagliflozin: Vasodilatory Effect on Isolated Rat Coronary Arteries
by: Sooyeon Choi, et al.
Published: (2023-11-01)

Dapagliflozin Mitigates Hypotension in Lipopolysaccharide-Induced Acute Inflammation Independent of Glycemia Level
by: Wael A. Alanazi, et al.
Published: (2023-06-01)

Exenatide and Dapagliflozin Combination Enhances Sertoli Cell Secretion of Key Metabolites for Spermatogenesis
by: João C. Ribeiro, et al.
Published: (2022-05-01)

Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
by: Hao Z, et al.
Published: (2022-07-01)

Cost‐effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China
by: Younan Yao, et al.
Published: (2020-12-01)

Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region
by: Chia-Te Liao, et al.
Published: (2021-10-01)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
by: Hilmi Alnsasra, et al.
Published: (2023-08-01)

Improved Manufacturability and In Vivo Comparative Pharmacokinetics of Dapagliflozin Cocrystals in Beagle Dogs and Human Volunteers
by: Sangho Cho, et al.
Published: (2021-01-01)

Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia
by: Osonoi T, et al.
Published: (2023-06-01)

Cost‐utility analysis of add‐on dapagliflozin in heart failure with reduced ejection fraction in the Philippines
by: Victor L. Mendoza, et al.
Published: (2021-12-01)

Targeting Autophagy, Apoptosis, and Oxidative Perturbations with Dapagliflozin Mitigates Cadmium-Induced Cognitive Dysfunction in Rats
by: Hany H. Arab, et al.
Published: (2023-11-01)

Stability indicating HPLC method for the simultaneous determination of dapagliflozin and saxagliptin in bulk and tablet dosage form
by: Deepan Thiyagarajan, et al.
Published: (2018-03-01)

A case report of euglycemic ketoacidosis due to dapagliflozin treatment
by: Murat Çalapkulu, et al.
Published: (2021-03-01)

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
by: Gupta M, et al.
Published: (2021-08-01)

Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial
by: Fahmida Ilyas, et al.
Published: (2021-10-01)

Benefit or Risk in Patient with Type 1 Diabetes Based on Appropriated Dosage of Dapagliflozin: A Case Report
by: Yan Tian, et al.
Published: (2023-04-01)